| Primary |
| Chronic Myeloid Leukaemia |
48.3% |
| Acute Lymphocytic Leukaemia |
16.4% |
| Gastrointestinal Stromal Tumour |
13.1% |
| Pulmonary Arterial Hypertension |
4.3% |
| Prophylaxis |
3.8% |
| Hypertension |
3.0% |
| Glioblastoma Multiforme |
2.0% |
| Acute Myeloid Leukaemia |
1.0% |
| Angina Pectoris |
1.0% |
| Interstitial Lung Disease |
0.8% |
| Scleroderma |
0.8% |
| Hyperuricaemia |
0.7% |
| Diabetes Mellitus |
0.7% |
| Dyspepsia |
0.7% |
| Hypereosinophilic Syndrome |
0.7% |
| Insomnia |
0.7% |
| Chronic Graft Versus Host Disease |
0.5% |
| Chronic Obstructive Pulmonary Disease |
0.5% |
| Hypothyroidism |
0.5% |
| Atrial Fibrillation |
0.5% |
|
| Death |
50.9% |
| Neoplasm Malignant |
14.1% |
| Vomiting |
3.8% |
| Pneumonia |
3.3% |
| Thrombocytopenia |
2.6% |
| Cd4 Lymphocytes Increased |
2.4% |
| Pyrexia |
2.4% |
| Renal Failure Chronic |
2.2% |
| Drug Resistance |
2.1% |
| Neoplasm Progression |
2.1% |
| Sepsis |
1.7% |
| Anaemia |
1.5% |
| Drug Ineffective |
1.5% |
| Dyspnoea |
1.5% |
| Chronic Myeloid Leukaemia |
1.4% |
| Gene Mutation Identification Test Positive |
1.4% |
| Myocardial Infarction |
1.4% |
| Therapeutic Response Decreased |
1.4% |
| Blast Crisis In Myelogenous Leukaemia |
1.2% |
| Nausea |
1.2% |
|
| Secondary |
| Chronic Myeloid Leukaemia |
31.3% |
| Acute Lymphocytic Leukaemia |
22.5% |
| Gastrointestinal Stromal Tumour |
9.0% |
| Prophylaxis |
7.8% |
| Dyspepsia |
4.1% |
| Pulmonary Arterial Hypertension |
2.5% |
| Colorectal Cancer Stage Iv |
2.3% |
| Non-hodgkin's Lymphoma |
2.1% |
| Hypertension |
2.0% |
| Immunosuppression |
1.9% |
| Acute Myeloid Leukaemia |
1.8% |
| Acute Myeloid Leukaemia Recurrent |
1.8% |
| B Precursor Type Acute Leukaemia |
1.8% |
| Product Used For Unknown Indication |
1.8% |
| Chronic Graft Versus Host Disease |
1.6% |
| Pain |
1.4% |
| Graft Versus Host Disease |
1.2% |
| Pulmonary Hypertension |
1.1% |
| Aortic Valve Stenosis |
1.0% |
| Nausea |
1.0% |
|
| Death |
11.3% |
| Neoplasm Malignant |
9.1% |
| Pyrexia |
7.4% |
| Blood Alkaline Phosphatase Increased |
6.1% |
| Cd4 Lymphocytes Increased |
6.1% |
| Skin Lesion |
6.1% |
| Vomiting |
5.6% |
| Acute Myeloid Leukaemia |
5.2% |
| Nausea |
4.8% |
| Chronic Myeloid Leukaemia |
4.3% |
| Thrombocytopenia |
4.3% |
| Scrotal Swelling |
3.9% |
| Blood Creatinine Increased |
3.5% |
| Hepatotoxicity |
3.5% |
| Normal Newborn |
3.5% |
| Pleural Effusion |
3.5% |
| Cerebral Infarction |
3.0% |
| Drug Ineffective |
3.0% |
| Hallucination |
3.0% |
| Pancytopenia |
3.0% |
|
| Concomitant |
| Chronic Myeloid Leukaemia |
16.6% |
| Acute Lymphocytic Leukaemia |
12.5% |
| Respiratory Tract Infection |
10.4% |
| Prophylaxis |
9.0% |
| Nephrogenic Anaemia |
7.6% |
| Stem Cell Transplant |
5.2% |
| Chemotherapy |
4.8% |
| Drug Use For Unknown Indication |
3.5% |
| Asthma |
3.1% |
| Acute Myeloid Leukaemia |
2.8% |
| Acute Promyelocytic Leukaemia |
2.8% |
| Bone Marrow Transplant |
2.8% |
| Colorectal Cancer Metastatic |
2.8% |
| Insomnia |
2.8% |
| Parkinson's Disease |
2.8% |
| Product Used For Unknown Indication |
2.8% |
| Hypertension |
2.1% |
| Idiopathic Thrombocytopenic Purpura |
2.1% |
| Influenza |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
1.7% |
|
| White Blood Cell Count Decreased |
9.4% |
| Aplastic Anaemia |
7.8% |
| Angina Pectoris |
6.3% |
| Hepatic Failure |
6.3% |
| Rash |
6.3% |
| Staphylococcal Infection |
6.3% |
| Vomiting |
6.3% |
| Acute Leukaemia |
4.7% |
| Chronic Myeloid Leukaemia |
4.7% |
| Pleural Effusion |
4.7% |
| Pyrexia |
4.7% |
| Spinal Compression Fracture |
4.7% |
| Spinal Cord Disorder |
4.7% |
| Stenotrophomonas Infection |
4.7% |
| Cerebral Ischaemia |
3.1% |
| Disseminated Intravascular Coagulation |
3.1% |
| Fluid Retention |
3.1% |
| Fusarium Infection |
3.1% |
| Glioblastoma Multiforme |
3.1% |
| Multi-organ Failure |
3.1% |
|
| Interacting |
| Pulmonary Arterial Hypertension |
36.4% |
| Chronic Myeloid Leukaemia |
22.7% |
| Hypercholesterolaemia |
22.7% |
| Hypokalaemia |
9.1% |
| Acute Lymphocytic Leukaemia |
4.5% |
| Stem Cell Transplant |
4.5% |
|
| Blood Creatine Phosphokinase Increased |
33.3% |
| Alanine Aminotransferase Increased |
22.2% |
| Gastrointestinal Haemorrhage |
22.2% |
| Drug Interaction |
11.1% |
| Myositis |
11.1% |
|
